PubMed Health⌕ Search

PubMed · 12908561

Breast cancer gene expression analysis--the case for dynamic profiling.

Abstract

Cancer is a complicated disease with each individual tumor exhibiting to a variable degree a set of overlapping phenotypes that include abnormal proliferation and cell survival, genetic instability, tissue invasion, metastasis and angiogenesis. Each of these pathophysiological functions requires abnormal signaling that fails to respect the normal restraints imposed on healthy cells through homeostatic regulation. Understanding of deregulated gene expression is therefore an essential goal for cancer research because unraveling this problem will provide insights into the fundamental nature of cancer as well as provide opportunities for therapeutic intervention. Gene expression profiling is a remarkable technique that addresses this complexity by documenting the expression of thousands of genes at the level of mRNA abundance. From the standpoint of clinical investigation, the initial focus of gene profiling experiments has been on screening primary tumors for markers of poor prognosis. However this is only a first step in demonstrating the utility of this technique. Future advances will focus on understanding the evolution of an organ confined primary cancer to a treatment resistant lethal systemic disease through repeated tumor sampling and analysis, an approach termed in this paper "dynamic profiling". Using breast cancer endocrine therapy as an example our initial approaches to dynamic profiling will be described.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Matthew J Ellis. 2003. Breast cancer gene expression analysis--the case for dynamic profiling.. https://pubmed.ncbi.nlm.nih.gov/12908561/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Differential Effectiveness of Adjuvant Endocrine Therapy According to Menopausal Status, Body Mass Index, and Molecular Subtype in Hormone Receptor-Positive Breast Cancer.

The effectiveness of adjuvant endocrine therapy for hormone receptor-positive (HR+) breast cancer (BC) varies according to menopausal status, body mass index (BMI), and tumor biology. We evaluated the association between selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), and BC-specific mortality according to menopausal status, BMI, and molecular subtype in a nationwide Korean cohort. We analyzed data from 31,030 patients with HR+ BC who were registered in the Korean Breast Cancer Society Registry, diagnosed between 2000 and 2008, and followed through 2013. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for BC-specific mortality after adjusting for demographic and clinical factors. Of the 31,030 patients, 19,634 received SERM therapy, and 3,354 received AI therapy. SERM use was associated with lower BC-specific mortality in premenopausal women (HR, 0.75; 95% CI, 0.63-0.91), whereas AI therapy was more strongly associated with lower BC-specific mortality among postmenopausal women (HR, 0.76; 95% CI, 0.61-0.94). Lower BC-specific mortality was observed among patients with a BMI ≥ 23 kg/m² who received SERM (HR, 0.84; 95% CI, 0.72-0.98) or AI therapy (HR, 0.78; 95% CI, 0.62-0.99). The strongest association with lower BC-specific mortality was observed in postmenopausal women with luminal B tumors (HR, 0.59; 95% CI, 0.42-0.83). The association between adjuvant endocrine therapy and BC-specific mortality differed according to menopausal status, BMI, and molecular subtype. These findings suggest that menopausal status, BMI, and molecular subtype are important considerations when evaluating endocrine treatment strategies.

Aromatase Inhibitors↗